Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
NCT ID: NCT00346008
Last Updated: 2013-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2500 participants
OBSERVATIONAL
2005-10-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
NCT00450593
Iceland Screens, Treats or Prevents Multiple Myeloma
NCT03327597
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
NCT00897481
Differential Risks for Melanoma: p16 and DNA Repair
NCT00615095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
* Assess the feasibility of mutation detection using sequencing and HPLC.
* Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.
OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mutation analysis
high performance liquid chromatography
laboratory biomarker analysis
questionnaire administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Iceland Genomics Corporation
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alisa Goldstein, PhD
Role: STUDY_CHAIR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Iceland Genomics Corporation
Reykjavik, , Iceland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-06-C-N026
Identifier Type: -
Identifier Source: secondary_id
CDR0000551606
Identifier Type: REGISTRY
Identifier Source: secondary_id
NBCI-01-087-CM
Identifier Type: -
Identifier Source: secondary_id
999906026
Identifier Type: -
Identifier Source: secondary_id
NBCI-03-033-CM
Identifier Type: -
Identifier Source: org_study_id
NCT00482534
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.